Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.77 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285540 | 0.91 | MET (0.75) | METIDO1CHEK1PIK3CAGRIN1 | |
| SCHEMBL2285375 | 0.87 | MET (1.00) | METIDO1TLR9TLR8TLR7 | |
| SCHEMBL2286491 | 0.85 | MET (0.70) | METCHEK1TLR9TLR8TLR7 | |
| SCHEMBL2185742 | 0.85 | MET (0.79) | METIDO1CHEK1 | |
| SCHEMBL2286378 | 0.83 | MET (1.00) | MET | |
| SCHEMBL2356914 | 0.83 | MET (0.67) | METCHEK1PIK3CA | |
| SCHEMBL2288589 | 0.74 | MET (1.00) | MET | |
| SCHEMBL2289810 | 0.73 | MET (1.00) | MET | |
| SCHEMBL2288836 | 0.73 | MET (0.82) | MET | |
| SCHEMBL2186157 | 0.71 | MET (0.72) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | claimed |
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010046013-A1 | AZAINDOLE DERIVATIVE | MERCK PATENT GMBH (DE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | AZI2, ABL1, RET | MET 8/4885NPBWR1 3130/4885IDO1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.